The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
Antonio Marcilio Padula Omuro
Consultant or Advisory Role - Novocure; Roche
Thomas Joseph Kaley
No relevant relationships to disclose
Elena Pentsova
No relevant relationships to disclose
Lisa Marie DeAngelis
No relevant relationships to disclose
Walter John Urba
No relevant relationships to disclose
Matthew Hiram Taylor
Consultant or Advisory Role - Tactical Therapeutics
Research Funding - Tactical Therapeutics
Barry Douglas Anderson
No relevant relationships to disclose
Greg Gorman
Consultant or Advisory Role - Tactical Therapeutics
Research Funding - Tactical Therapeutics
Sean McLean
No relevant relationships to disclose
Rashida A. Karmali
Employment or Leadership Position - Tactical Therapeutics
Stock Ownership - Tactical Therapeutics